Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors

Journal of Sexual Medicine

Volumn 7, Issue 3, 2010, Pages 1237-1246

  Schnetzler, Gabriel ^a   Banks, Ian ^b   Kirby, Mike ^c   Zou, Kelly H ^d   Symonds, Tara ^e  

^a Prism Ideas Ltd   (Switzerland)

^b LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d PFIZER INC   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Counterfeit drugs; E Medicine; Erectile dysfunction; Illicit drugs; Internet; Phosphodiesterase type 5 inhibitor; Sildenafil; Tadalafil; Unapproved medicines; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED STUDY; DOCTOR PATIENT RELATION; ERECTILE DYSFUNCTION; GERMANY; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; INTERNET; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PURCHASING; QUESTIONNAIRE; UNITED KINGDOM;

EID: 77950821266     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01674.x     Document Type: Article

References (36)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994, 151:54-61.
2. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004, 1:6-23.
3. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: An update. Eur Urol 2006, 49:806-15.
4. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003, 15:63-71.
5. Mulhall J, King R, Glina S, Hvidsten K. Importance of and satisfaction with sex among men and women worldwide: Results of the global better sex survey. J Sex Med 2008, 5:788-95.
6. Jones MJ. Internet-based prescription of sildenafil: A 2104-patient series. J Med Internet Res 2001, 3:E2.
7. Leusink PM, Aarts E. Treating erectile dysfunction through electronic consultation: A pilot study. J Sex Marital Ther 2006, 32:401-7.
8. Munger MA, Stoddard GJ, Wenner AR, Bachman JW, Jurige JH, Poe L, Baker DL. Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. Mayo Clin Proc 2008, 83:890-6.
9. Viagra's licence and the Internet. Lancet 1998, 352:751. [No author listed]
10. Armstrong K, Schwartz JS, Asch DA. Direct sale of sildenafil (Viagra) to consumers over the Internet [see comments]. N Engl J Med 1999, 341:1389-92.
11. Eysenbach G. Online prescribing of sildenafil (Viagra) on the World Wide Web. J Med Internet Res 1999, 1:e10.
12. Jackson G. Faking it: The dangers of counterfeit medicine on the Internet. Int J Clin Pract 2009, 63:181.
13. Kao SL, Chan CL, Tan B, Lim CC, Dalan R, Gardner D, Pratt E, Lee M, Lee KO. An unusual outbreak of hypoglycemia. N Engl J Med 2009, 360:734-6.
14. Dorsey PJ, Hellstrom WJG. The illicit sale of medications for the treatment of erectile dysfunction: Available at: http://www.medscape.com/viewarticle/566897. accessed July 7, 2009
15. Crosby R, Diclemente RJ. Use of recreational Viagra among men having sex with men. Sex Transm Infect 2004, 80:466-8.
16. Korkes F, Costa-Matos A, Gasperini R, Reginato PV, Perez MD. Recreational use of PDE5 inhibitors by young healthy men: Recognizing this issue among medical students. J Sex Med 2008, 5:2414-8.
17. Santtila P, Sandnabba NK, Jern P, Varjonen M, Witting K, von der Pahlen B. Recreational use of erectile dysfunction medication may decrease confidence in ability to gain and hold erections in young males. Int J Impot Res 2007, 19:591-6.
18. Aldridge J, Measham F. Sildenafil (Viagra) is used as a recreational drug in England. BMJ 1999, 318:669.
19. McCambridge J, Mitcheson L, Hunt N, Winstock A. The rise of Viagra among British illicit drug users: 5-year survey data. Drug Alcohol Rev 2006, 25:111-3.
20. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005, 45:63-72. quiz 73-65
21. Sugar SJ. Reply to " Viagra: The risks of recreational use." Am J Med 2006, 119:92-3.
22. Banks I, Kirby M, Marfatia A, Symonds T, Carlsson M, Schnetzler G. Assessment, in a general population of men, of men's interaction with the healthcare system to obtain phosphodiesterase type 5 inhibitors. Presented at: Joint Congress of the European and International Societies for Sexual Medicine; December 7-11, 2008; Brussels, Belgium
23. O'Donnell AB, Araujo AB, Goldstein I, McKinlay JB. The validity of a single-question self-report of erectile dysfunction. J Gen Intern Med 2005, 20:515-9.
24. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): A 5-year review of research and clinical experience. Int J Impot Res 2005, 17:307-19.
25. Data on file 2008, [No author listed], Pfizer Oy, Helsinki, Finland
26. European Commission Eurostat. Average population by sex and five-year age groups. http://nui.epp.eurostat.ec.europa.eu/nui/show.do?dataset=demo_ppavg&lang=en, [No author listed], Available at: (accessed July 14, 2009
27. 2007 customs seizures of counterfeit goods-Frequently asked questions: Available at: http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/08/310&format=HTML&aged=0&language=en&guiLanguage=en (accessed July 7, 2009). 2008, European Commission
28. Blok-Tip L, Vogelpoel H, Vredenbregt MJ, Barends DM, de Kaste D. Counterfeits and imitations of Viagra® and Cialis® tablets: trends and risks to public. A survey of the analyses carried out at the Dutch National Institute for Public Health and the Environment in the time period 2000-2004. 2005, http://www.rivm.nl/bibliotheek/rapporten/267041001.pdf, Available at: (accessed September 24, 2009
29. Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D. Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra: A 2005-2006 update. 2007, http://www.rivm.nl/bibliotheek/rapporten/370030001.pdf, Available at: (accessed September 24, 2009
30. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007, 61:2019-25.
31. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294:2996-3002.
32. Banks I. No man's land: Men, illness, and the NHS. BMJ 2001, 323:1058-60.
33. Baumgartner MK, Hermanns T, Cohen A, Schmid DM, Seifert B, Sulser T, Strebel RT. Patients' knowledge about risk factors for erectile dysfunction is poor. J Sex Med 2008, 5:2399-404.
34. Claes H, Opsomer R-J, Andrianne RS, Vanbelle S, Albert A, Vanderdonck F. Characteristics and expectations of patients with erectile dysfunction: Results of the SCORED study. Int J Impot Res 2008, 20:418-24.
35. Cappelleri JC, Stecher VJ. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective. Int J Impot Res 2008, 20:343-57.
36. Mulhall JP, Althof SE, Brock GB, Goldstein I, Jünemann K-P, Kirby M. Erectile dysfunction: Monitoring response to treatment in clinical practice-recommendations of an international consensus panel. J Sex Med 2007, 4:448-64.